Image Source: © motortion | Megapixl.com
- Radiopharm has joined hands with Isotopia to gain access to the latter’s flagship product, Lutetium-177.
- The radioisotope has shown significant promise in treating a variety of late-stage cancers.
- The Company plans to use the new product to transform outcomes for patients suffering from oncological diseases.
Radiopharm Theranostics Limited (ASX:RAD) has taken another major step to quickly progress its broad clinical pipeline.
In a major development, the clinical-stage radiotherapeutics company has entered into a supply agreement with Isotopia Molecular Imaging (Isotopia) for Lutetium-177 N.C.A. The development aligns well with the Company’s efforts to progress the next generation of radiopharmaceutical therapies for cancer treatment.
Established in 2006, Isotopia Molecular Imaging Ltd. is a leading supplier of Lutetium-177 (177Lu), which has shown significant promise in treating a variety of late-stage cancers. The firm creates collaborations between the scientific and medical communities to boost the development and experiment with new markers for imaging applications and molecular therapy.
Radiopharm has a pipeline of six distinct and highly differentiated platform technologies in pre-clinical and clinical stages of development.
Lutetium-177 radioisotope - Promise to cure late-stage cancers
Lutetium-177 is a key isotope required for multiple clinical trials in Radiopharm’s clinical pipeline.
Under the agreement, Isotopia will provide high-quality Lutetium-177 N.C.A to RAD to be utilised in clinical research, development, production, and early-stage commercialisation of its diagnostic and therapeutic products. The deal will now enable Radiopharm to speed up the development of its several assets.
Effective from 14 June 2022, the supply agreement is for an initial period of two years. The agreement will automatically renew for successive one-year periods unless agreed otherwise by either party.
Brain tumor technology in RAD portfolio
Recently, RAD also signed an exclusive sublicensing agreement with NeoIndicate for a PTPµ-targeted radiopharmaceutical agent.
Under the contract, the Company gained rights to develop the PTPµ-targeted agent as an imaging diagnostic and as a targeted radiopharmaceutical theranostic as part of its clinical development pipeline.
The technology has demonstrated promising pre-clinical data in human glioblastoma tumour models, and its Phase 1 brain tumor imaging study will start in about 12 months.
At the time of writing this article (FRI 17 JUN 11:38 AM AEST), shares of Radiopharm were trading at AU$0.140.
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and